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Abstract
Purpose: Ensuring high quality, evidence-based radiation therapy for patients is of the upmost importance. As a part of the largest integrated health system in America, the Department of Veterans Affairs National Radiation Oncology Program (VA-NROP) established a
quality surveillance initiative to address the challenge and necessity of providing the highest quality of care for veterans treated for
cancer.
Methods and Materials: As part of this initiative, the VA-NROP contracted with the American Society for Radiation Oncology to
commission 5 Blue Ribbon Panels for lung, prostate, rectal, breast, and head and neck cancers experts. This group worked collaboratively with the VA-NROP to develop consensus quality measures. In addition to the site-speciﬁc measures, an additional Blue Ribbon
Panel comprised of the chairs and other members of the disease sites was formed to create 18 harmonized quality measures for all 5 sites
(13 quality, 4 surveillance, and 1 aspirational).
Conclusions: The VA-NROP and American Society for Radiation Oncology collaboration have created quality measures spanning 5
disease sites to help improve patient outcomes. These will be used for the ongoing quality surveillance of veterans receiving radiation
therapy through the VA and its community partners.
Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.

Introduction
The Department of Veterans Affairs (VA) is considered the largest integrated health care system in the
United States with 1293 health care facilities, which
includes 171 VA medical centers and 1112 outpatient
clinics providing care to around 9 million veterans.1 In
2016, the VA launched the radiation oncology quality surveillance (VA-ROQS) program to assess the variation and
quality of care of the radiation oncology centers in the
VA hospitals.2 In collaboration with the American Society
for Radiation Oncology (ASTRO), quality measures

(QM) were developed by disease-site expert panels to
assess the care for intermediate and high-risk prostate
cancers, as well as stage III non-small cell lung cancer.3
Given that 50% of veterans are users of both VA and nonVA community care services, in 2019, the VA-ROQS set
out to assess the performance of non-VA community care
radiation oncology providers using the prostate cancer
QM.3 There were considerable challenges in obtaining the
QMs, with only 28% of non-VA community care patient
treatments able to be reviewed. To ensure the quality of
care and adherence to common standards, the VA
National Radiation Oncology Program (NROP) and
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ASTRO initiated a collaborative team effort to form a
framework of quality metrics for lung, prostate, rectal,
breast, and head and neck cancers. The main aim is to
ensure a comprehensive framework on the adequacy of
initial consultation, work up, simulation, treatment planning, treatment delivery, and follow-up of patients with
cancer. The underpinnings that govern this approach are
to ensure compliance to a predeﬁned framework of evidence-based quality metrics that are easy to follow and
practically feasible to adhere to without undue time-consuming expectations that would potentially impede quality care. A Blue Ribbon Panel of content experts was
established to form a consensus framework that could
potentially ensure conformity in or of practice patterns
across the radiation oncology community in both academic and private practice settings. The workﬂow is summarized in this article.

Methods and Materials
The NROP, in collaboration with ASTRO, formed 5
Blue Ribbon Panels of ASTRO-designated disease-site
experts for lung, prostate, rectal, breast, and head and
neck cancers. This group worked collaboratively with
NROP to develop consensus quality measures. The groups
developed comprehensive quality measures for each disease site. ASTRO staff performed an environmental scan
to assess clinical practice guidelines, consensus recommendations, and existing measures to identify potential
measure concepts. This included publicly available formal
guidelines and resources (eg, Consumer Assessment of
Healthcare Providers and Systems) to identify recommendations from reputable organizations (eg, National Comprehensive Cancer Network, Commission on Cancer,
Medicare, and the International Consortium for Health
Outcomes Measurement). Each panel developed an initial
list of measures that required a prespeciﬁed threshold of
≥75% agreement by panelists.
Each panel then conducted a series of calls to discuss
each measure and reﬁne the measure speciﬁcations (eg,
deﬁnitions of each numerator, denominator, inclusion
criteria, and exclusions). Two VA radiation oncologists,
serving as ex-ofﬁcio members, participated and were
available to answer questions related to workﬂows and
patient populations unique to VA facilities. Each measure
was categorized into 1 of 3 types. “Quality measures”
assess current standards of care. A subset of these quality
measures, felt to be of critical clinical importance, was
identiﬁed as “high potential effect measures.” The term
“aspirational measures” was used to indicate those performance measures not currently standardized in common
practice, but useful as ambitious goals for clinical practice.
“Surveillance measures” focused on concepts addressing
population health. After the completion of the 5 disease
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sites, a separate harmonization measure panel convened.
It was comprised of the ASTRO staff and 2 members
from each disease site (the chair and 1 other member).
Overlapping measures and general concepts that were
common to all disease sites were identiﬁed and a total of
18 harmonization measures were created.
Based on the draft measures, ASTRO staff created
decision trees for each measure to depict the measure
logic in a series of steps with a binary outcome (Supplementary Materials). These trees delineated the data element concepts and sequence of steps necessary to
calculate the measure score. The tree begins with the trigger for measurement (eg, radiation oncology consult
occurred), followed by narrowing to the appropriate
patient population and removal of patients who met measure exclusions. Once the ﬁnal patient population is identiﬁed, the numerator components result in either a “pass”
or “fail” outcome. Every panel also contained a medical
physicist who worked with ASTRO staff to develop draft
dose volume histogram (DVH) metrics from published
data and protocols. DVH metrics were either categorized
as constraints or informational. Constraints are metrics
used to evaluate the quality of the treatment plan and
establish dosimetric performance goals. The remaining
metrics, which help to characterize the general quality of
radiation delivery, are recorded for informational purposes, similar to the surveillance measures.

Results
The 5 disease-site speciﬁc manuscripts contain further
details of the process that were unique to each panel. After
the completion of the disease-speciﬁc measures, it was
decided to create a separate, ﬁnal harmonized measure
that included 18 measures that all sites had in common
(Tables 1−3; see Supplementary Materials, which provides more details regarding these measures), thus the disease-speciﬁc recommendations contain only the measures
that pertain to that site.

Discussion
Radiation oncology is quickly transforming to deliver
personalized adaptive care in hopes of improving oncologic outcomes. Radiation treatment planning is highly
individualized to the patient and thus there is considerable variability based on clinical practice preferences both
within and across institutions. A vital part of the quality
improvement effort will be ensuring the delivery of quality radiation therapy in clinics across the United States
both inside and outside of the VA. The importance of this
has been recognized for many years. A meta-analysis of 8
cooperative group trials found that radiation therapy
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Table 1

Consultation and workup

90

None

*Anatomic/pathologic
stage
documentation

Patients with documented evaluation of anatomic
stage, before or at the time of simulation, that
includes: 1. Primary tumor stage AND node
stage AND metastasis staging OR 2. AJCC
staging

100

None

H4

*Pathology report
review

Pathology report reviewed by the radiation
oncologist before simulation

100

Patients receiving palliative care

H5

Pregnancy screening

Documentation of pregnancy screening or refusal
before simulation for patients of childbearing
ability, between the ages of 15 and 55, with a
diagnosis of cancer receiving external beam
radiation therapy

100

Patients with a history of a
hysterectomy; patients with
documented history of
menopause; negative onset of
menarche

H6

*Prior radiation

Patients with documentation of prior radiation
status at the time of consult

100

None

H7

Implantable cardiac
device screening

All patients with a diagnosis of cancer receiving
radiation therapy, screened for an implantable
cardiac device before the simulation procedure

100

None

H8

Smoking status

Patients with a documentation of current smoking
status at the time of consult

90

None

Surveillance measures

H2

Enrolled clinical trial

Patients enrolled in a prospective oncology
clinical trial

N/A

None

Aspirational measures

H9

Smoking cessation
referral/counseling

Patients with a referral to a smoking cessation
program OR documentation of smoking
cessation counseling at the time of consult.

80

None

Measure details

Quality measures

H1

*Performance status

H3

Abbreviations: AJCC = American Joint Committee on Cancer; ECOG = Eastern Cooperative Oncology Group; KPS = Karnofsky Performance Status; N/A = not available; WHO = World Health Organization.
*
High potential effect measures
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All patients with a diagnosis of cancer with
documentation of performance status using a
standardized scale (ie, ECOG, WHO, KPS) at
the time of consult

Measure
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Exclusions

#
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Expected
performance %

Measure type

Simulation, treatment planning, and treatment

90

None

*Treatment plans peer
reviewed

Patients with documentation of peer review of treatment
plans by a radiation oncologist, which includes review
of: 1. Dose to target volumes AND 2. dose to organs
at risk before the sixth treatment day for conventional
fractionation regimen OR before the ﬁrst treatment
day for short course regimen

90

Patients receiving
palliative care

H14

Pain assessment/
quantiﬁed

Patients with pain intensity quantiﬁed at an ontreatment visit using a standardized instrument

90

None

H15

Plan of care for pain

Patients with a plan of care for pain at the on-treatment
visit when pain was quantiﬁed

90

None

H16

*Avoidance of
treatment breaks

Patients with an unplanned treatment break of 5 or more
treatments for conventional fractionation

90

Patients receiving
palliative care

H10

28 days from diagnosis
to any treatment

Patients who started radiation therapy OR systemic
therapy OR surgery within 28 calendar d after
conﬁrmed diagnosis

90

Patients receiving
palliative care

H11

21 days from consult to
any treatment

Patients who started radiation therapy OR systemic
therapy OR surgery within 21 calendar days after
oncology consult

90

Patients receiving
palliative care

Measure

Measure details

Quality measures

H12

*14 days from
simulation to ﬁrst
treatment

H13

Surveillance measures

*

High potential effect measures

ARTICLE IN PRESS

Exclusions

All patients who started radiation treatment within
14 days after simulation

#
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Expected
performance %

Measure type
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Table 3

Follow-up
Expected
performance %

Exclusions

Patients who have a treatment
summary report
completed within 30 days
of completing treatment

100

None

Patients with 1 follow-up visit
with a radiation oncologist
during the ﬁrst year
postradiation therapy

N/A

Patients with
metastatic disease

Measure type

#

Measure

Measure details

Quality measures

H17

Treatment summary
completion

Surveillance
measures

H18

Follow-up with a
radiation oncologist

Abbreviations: N/A = not available.

protocol deviations were correlated with treatment failure
and survival.4
Feasibility to perform widescale radiation therapy
quality assurance has been shown in the United States
through the efforts of the Quality Research in Radiation
Oncology process and internationally through the work
of the Global Clinical Trials Radiation Therapy Quality
Assurance Harmonization Group, which included the
European Organization for Research and Treatment of
Cancer, Radiation Therapy Oncology Group, and the
Trans-Tasman Radiation Oncology Group.5,6 Automated
quality assurance can streamline quality control processes
along with efforts to collect patient-speciﬁc data and
introduces standardized nomenclatures for structures and
DVH metrics that improve patient safety.7,8 The goal of
automated processes is to improve standardization and
heighten the quality of initial work up, treatment, and follow-up for the patients.
In 2013, ASTRO published the “Target Safely Campaign,” including a series of safety white papers that
emphasized not only reviews of radiation treatment plans
but also the importance of peer review of the whole team,
including action items for physicians, dosimetrists, therapists, and physicists.9 The importance of quality control
measures on lower gastrointestinal cancer has also been
speciﬁcally noted and echoes recommendations from the
Blue Ribbon Panel’s guidance, including an extended
quality control process starting at work up and including
follow-up procedures.10
Previously, the VA has introduced quality metrics developed by disease-site experts designed to operate in the background of daily practice. These efforts have been pioneered
through the establishment of the VA-ROQS program.2
Moving forward, the main goal of the VA clinical audit
algorithms in each cancer site will be assessment of performance-based indicators, speciﬁcally the use of evidencebased guidelines for patient-speciﬁc treatment decisions.
Signiﬁcant challenges remain, however, as only 28% of
the community care consults from the VA were available
for QM assessment.3 To overcome this challenge, the VA
is now in the process of developing an electronic infrastructure called the “Health Information and Gateway

Exchange” to collect patient-speciﬁc discrete values that
will be used to easily access measures for quality surveillance, treatment effectiveness, outcomes, and quality of
life assessment.

Conclusions
The VA has collaborated with ASTRO to develop QM
to help better serve our veterans with cancer. As the largest integrated health system in the United States with 41
radiation oncology departments that also work closely
with multiple community care partners across the country, it is imperative that all patients receive the highest
level of care both within and outside the VA. With the
development of these QM, published DVH constraints,
and simultaneous development of the automated tracking
Health Information and Gateway Exchange system, our
aim is to ensure that veterans will be able to receive the
highest quality of care, as they deserve, and that this
framework will serve as a generalizable model for others
to follow.

Supplementary materials
Supplementary material associated with this article can
be found in the online version at doi:10.1016/j.
prro.2022.05.015.
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